ESLA Stock — Estrella Immunopharma Inc.

Estrella Immunopharma Inc. (ESLA)

Updated October 16, 2026.

ESLA is a Stock. Total return is -95.6% over the past 5.1 years, 179.9 points behind SPY at 84.3%.

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors, with lead candidates EB103 in Phase I/II trials for diffuse large B-cell lymphoma and a platform called ARTEMIS designed to target CD19 and CD22 in hematologic malignancies. The company does not currently distribute to shareholders. This security appeals to investors with high risk tolerance who are willing to hold early-stage biotech companies with no established revenue or profits, betting on potential future clinical and commercial success.

ESLA performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.6% over the past 5.1 years, 179.9 points behind SPY at 84.3%. Over the past year its total return — price change plus distributions reinvested — is -73.3%. Its deepest 1-year drawdown was 89.7%.

ESLA key facts

Asset type

Stock

Asset class

Equity

Inception date

09/14/2021

Distribution frequency

None

Last close

$0.43 (as of 2026-10-16)

Market cap

$18,704,082

Average volume

4232553.0

Beta

0.932

Payout ratio

0.0%

EPS

$-0.25

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ESLA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 89.7%.

Who may consider ESLA — and who may not

It is a weaker fit for investors who need monthly cash flow (ESLA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ESLA

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions